Core Viewpoint - Goldman Sachs has raised the earnings per share (EPS) forecasts for Innovent Biologics (01801) for 2025 to 2027, reflecting a positive outlook on the company's financial performance despite some challenges in the market [1] Financial Performance - The product revenue for Innovent Biologics in the fourth quarter of last year was approximately 3.3 billion RMB, meeting Goldman Sachs' expectations, with a year-on-year growth of 60% from a relatively low base, remaining flat quarter-on-quarter [1] - The company's new product portfolio continues to show growth, with a quarterly increase of 13%, which offsets the weak performance of Tyvyt [1] - For the full year of 2025, product sales are expected to be strong, with a projected year-on-year growth of 45% to 11.9 billion RMB, marking the first time sales exceed the 10 billion RMB milestone, driven primarily by the growth in the biopharmaceutical business [1] Target Price and Rating - The target price for Innovent Biologics has been adjusted to 102.85 HKD from the previous 107.96 HKD, while maintaining a "Buy" rating [1]
高盛：信达生物去年产品销售强劲 目标价102.85港元